ISDA

Deposition Date 2025-02-11

Release Date 2025-08-06

Last Version Date 2025-08-27

Entry Detail

PDB ID:

9IB5

Keywords:

HYDROLASE

Title:

Structure of 18 (BI-2493) in complex with GDP-KRAS

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.01 Å

R-Value Free:

0.19

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:GTPase KRas
Gene (Uniprot):KRAS
Chain IDs:A
Chain Length:170
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P01116 Pfam ID:PF00071 EC:3.6.5.2

Ligand Molecules

EDO

GDP

VU6

Primary Citation

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.

Broker, J, Waterson, A.G, Hodges, T.R, Abbott, J.R, Arnold, A, Bottcher, J, Braun, N, Cui, J, Fuchs, J.E, Gerstberger, T, Gogg, S, Hanner, S, Herdeis, L, Howell, L.W, Mantoulidis, A, Mayer, M, Phan, J, Rocchetti, F, Sankar, K, Sarkar, D, Schaaf, O, Sensintaffar, J.L, Sun, Q, Wunberg, T, Fesik, S.W.Show

J.Med.Chem. 68 15649 15668 (2025)

PMID: 40709733 DOI: 10.1021/acs.jmedchem.5c00576

Abstact

KRAS is one of the most highly validated cancer targets. Here we describe the design and synthesis of two reversible pan-KRAS inhibitors, BI-2865 and BI-2493. From our KRASG12C inhibitor program, we identified BI-2865, a potent noncovalent KRAS inhibitor that showed cellular activity against a broad spectrum of KRAS alleles and selectivity against HRAS and NRAS. Spirocyclization led to the discovery of BI-2493, a highly rigid analogue exhibiting better potency, metabolic stability, and permeability. BI-2493 shows in vivo efficacy in various KRAS mutant and KRAS wild-type amplified xenograft models and represents a promising starting point for further optimization.

Legend

Protein

Chemical

Disease

Primary Citation of related structures